141.18% 0.024

Galera Therapeutics Inc (GRTX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt GRTX? Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Galera Therapeutics Inc Stock (GRTX) Company Profile

Galera Therapeutics Inc

Healthcare (1118)

Biotechnology (624)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

GRTX's Discussions on Twitter

Compare GRTX vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
GRTX Galera Therapeutics Inc	0.041	0	0	149.05M	-6.05M	1.9846
VRTX Vertex Pharmaceuticals Inc	438.71	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	761.85	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	746.42	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	318.85	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	162.43	35.01B	606.42M	-1.28B	-997.58M	-6.403

Galera Therapeutics Inc Stock (GRTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-08-10	Herabstufung	Piper Sandler	Overweight → Neutral
2021-10-19	Herabstufung	BTIG Research	Buy → Neutral
2021-10-19	Herabstufung	BofA Securities	Buy → Underperform
2021-04-26	Fortgesetzt	Credit Suisse	Outperform
2020-12-16	Hochstufung	Credit Suisse	Neutral → Outperform
2020-12-07	Eingeleitet	H.C. Wainwright	Buy
2019-12-02	Eingeleitet	BTIG Research	Buy
2019-12-02	Eingeleitet	BofA/Merrill	Buy
2019-12-02	Eingeleitet	Citigroup	Buy
2019-12-02	Eingeleitet	Credit Suisse	Neutral

Alle ansehen

Galera Therapeutics Inc Aktie (GRTX) Neueste Nachrichten

Finanzdaten der Galera Therapeutics Inc-Aktie (GRTX)

Galera Therapeutics Inc (GRTX)

Galera Therapeutics Inc Stock (GRTX) Company Profile

Compare GRTX vs VRTX, REGN, ARGX, ALNY, INSM

Galera Therapeutics Inc Stock (GRTX) Upgrades & Downgrades

Galera Therapeutics Inc Aktie (GRTX) Neueste Nachrichten

Galera Therapeutics schedules combined 2025 and 2026 annual meeting for May - Investing.com Australia

Galera Sets Deadlines for 2026 Combined Annual Meeting - TipRanks

Galera Therapeutics schedules combined 2025-2026 annual meeting for May 8, 2026; April 13 proposal deadline - TradingView

Galera Therapeutics (GRTX) sets 2026 meeting date and April 13 proposal deadline - Stock Titan

Galera Therapeutics 10-K: Revenue $0, EPS $0.64 on $149.0M Net Income - TradingView

Galera Therapeutics (GRTX) exits radiotherapy, bets on pan-NOS breast cancer drug - Stock Titan

Galera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener

GRTX (Galera Therapeutics) NonCurrent Deferred Revenue : $0.00 Mil (As of Sep. 2025) - GuruFocus

Galera Therapeutics Sells Dismutase Mimetics Portfolio to Biossil in $108.5 Million Deal - MSN

GRTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Galera Therapeutics Updates Preferred Stock Conversion Provisions - TipRanks

Galera Therapeutics (GRTX) grants board discretion on Series B conversion - Stock Titan

Galera Therapeutics Grants Retention Bonus to Key Officer - TipRanks

Doylestown’s Aprea Therapeutics Names Industry Veteran as Chief Medical Advisor - BUCKSCO.Today

Aprea Therapeutics, Inc. Appoints Eugene Kennedy as Chief Medical Advisor - marketscreener.com

Galera Therapeutics completes acquisition of Nova Pharmaceuticals - Intellectia AI

Malvern-based Galera Therapeutics Secures New Lease on Life with Acquirement Underway - MSN

Head to Head Analysis: Lite Strategy (NASDAQ:LITS) and Galera Therapeutics (NASDAQ:GRTX) - Defense World

GRTX (Galera Therapeutics) EV-to-OCF : 0.32 (As of Dec. 19, 2025) - GuruFocus

Chmn Sorensen Sells 70,000 ($1.4K) Of Galera Therapeutics Inc [GRTX] - TradingView

GRTX Form 4: CEO Sorensen reports 70,000-share stock sale - Stock Titan

Chmn Sorensen Files To Sell 70,000 Of Galera Therapeutics Inc [GRTX] - TradingView — Track All Markets

Galera Therapeutics, Inc. SEC 10-Q Report - TradingView

Galera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener

[10-Q] Galera Therapeutics, Inc. Quarterly Earnings Report | GRTX SEC FilingForm 10-Q - Stock Titan

Deal Watch: GSK To Tap AN2’s Boron Chemistry Approach In Tuberculosis R&D - Citeline News & Insights

Aprea Therapeutics Reports Early Signs of Activity in APR-1051 Cancer Trial - MyChesCo

Canadian company purchases Galera Therapeutics’ dismutase mimetics portfolio - Pennsylvania Business Report -

Galera Therapeutics Sells Assets to Biossil Inc. - TipRanks

Biossil to acquire Galera’s dismutase mimetics portfolio for up to $105M - MSN

Galera Therapeutics Acquires Dismutase Mimetics Portfolio by Biossil For $105 Million - citybiz

Galera Therapeutics (GRTX) Sells Asset Portfolio to Biossil - GuruFocus

Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million - Yahoo Finance

Malvern firm selling drug portfolio in potential $105M deal after FDA setback - The Business Journals

Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan

Oral Mucositis Market Size & Share | Industry Report, 2033 - Grand View Research

NanoCell Therapeutics Expands Scientific Advisory Board With Global Experts in Gene Therapy and Clinical Development - MyChesCo

Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN) - The Lancet

Legend Biotech CorporationAmerican Depositary Shares (NQ: - FinancialContent

Galera Therapeutics Amends Royalty Agreement with Clarus - The Globe and Mail

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight - Yahoo Finance

Windtree Therapeutics to Launch BNB Crypto Treasury Strategy in Groundbreaking $200 Million Deal - MyChesCo

Warrington’s Windtree Therapeutics Acquires Waste Management Company - BUCKSCO.Today

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - GlobeNewswire

Oral Mucositis Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire

Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire

Galera Therapeutics Inc. (GRTX) reports earnings - qz.com

Chemotherapy Oral Mucositis Market Trends 2025-2035 - Future Market Insights

Festive biotech M&A spree sees Poolbeg combine with Hookipa, while Vincerx braces for layoffs - Fierce Biotech

Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals

Radiation Induced Esophagitis Market Set to Grow Substantially Through 2032, DelveInsight Projects | Galera Therapeutics - The Globe and Mail

Finanzdaten der Galera Therapeutics Inc-Aktie (GRTX)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie GRTX